Use access key #2 to skip to page content.
$40.53 1.30 (3.31%)
7/8/2008 4:00 PM

ImClone Systems, Inc. (IMCL)

CAPS Rating:
****

A biopharmaceutical company which advances oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.

View All Commentary (IMCL)

Recs

0

Avatar benoitlj (95.93) Submitted: 4/20/07 7:51 PM : Outperform Start Price: $42.02 IMCL Score: 10.72

Erbitux will be shown to be effective in treatment of lung cancer vastly increasing the number of patients who can use it.

Report this Post Replies: 0 | Reply

Featured Broker Partners